• Markets
    • icon
  • Companies
AFP · ASX

AFT Pharmaceuticals Ltd. (ASX:AFP)

AU$2.85

 -0.08 (-2.73%)
ASX:Live
26/07/2024 03:59:19 PM
Near Resistance HALO Ords HALO Dividend Growth HALO Capital Efficiency GROWTH AUS +2
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

AFP Overview

AFP Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Strong

GARP

Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Weak

Earnings

Neutral

Growth

Earnings

Strong

Dividends

Very Weak

Quality

Capital Efficiency

Very Weak

Balance Sheet

Neutral

About AFP

Website

N/A

Telephone

64.800.423.823

Address

Level 1 129 Hurstmere Road, Takapuna Nielsen House Auckland 0622

Description

AFT Pharmaceuticals Ltd. engages in the development, licensing, and distribution of medical and pharmaceutical products. It operates through the following geographical segments: Australia, New Zealand, Asia, and Rest of the World. The Australia segment caters to the Australian market. The New Zealand segment focuses on the head office function, supplier relationships and procurement of stock, and regulatory, marketing, and finance activities of the group. The Asia segment relates in the sales activities in Brunei, Hong Kong, Malaysia, Philippines, Singapore, and Vietnam markets. The Rest of the World segment consists of out licensing of internet protocol developments to markets in which the firm does not have a presence and the export of products to export markets. The company was founded by Hartley Atkinson and Marree Atkinson on September 4, 1997 and is headquartered in Auckland, New Zealand.

AFP Price Chart

Key Stats

Market Cap

AU$285.08M

PE

18.20

EV/EBITDA

12.6

Dividends Overview

DIV Yield

.6%

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 2.43 - 3.53

Trade Value (12mth)

AU$646.00

1 week

5.02%

1 month

3.53%

YTD

-11.21%

1 year

-13.82%

All time high

5.25

Key Fundamentals

EPS 3 yr Growth

101.500%

EBITDA Margin

13.40%

Operating Cashflow

$26m

Free Cash Flow Return

N/A

ROIC

N/A

Interest Coverage

9.10

Quick Ratio

N/A

Other Data

Shares on Issue (Fully Dilluted)

105m

HALO Sector

Healthcare

Next Company Report Date

22-May-25

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

AFP Announcements

Latest Announcements

Date Announcements

09 July 24

AFT agrees distribution for Crystaderm in China

×

AFT agrees distribution for Crystaderm in China

01 July 24

Notice of ASM

×

Notice of ASM

01 July 24

Retirement of Anita Baldauf

×

Retirement of Anita Baldauf

21 June 24

Update - Dividend/Distribution - AFP

×

Update - Dividend/Distribution - AFP

04 June 24

AFT to launch Maxigesic Rapid in the United States

×

AFT to launch Maxigesic Rapid in the United States

31 May 24

Annual Meeting and Closing Date for Director Nominations

×

Annual Meeting and Closing Date for Director Nominations

23 May 24

AFT reports record revenue and earnings

×

AFT reports record revenue and earnings

23 May 24

AFT reports record revenue and earnings - presentation

×

AFT reports record revenue and earnings - presentation

23 May 24

FY2024 Annual Report

×

FY2024 Annual Report

23 May 24

APP 2

×

APP 2

23 May 24

Distribution notice

×

Distribution notice

23 May 24

Dividend/Distribution - AFP

×

Dividend/Distribution - AFP

15 May 24

Becoming a substantial holder

×

Becoming a substantial holder

01 May 24

AFT Licenses Maxigesic IV in Brazil

×

AFT Licenses Maxigesic IV in Brazil

24 April 24

AFT,Massey Ventures,Gilles McIndoe to develop scar treatment

×

AFT,Massey Ventures,Gilles McIndoe to develop scar treatment

04 March 24

AFT makes further progress in international markets

×

AFT makes further progress in international markets

16 February 24

AFT updates operating profit guidance to $23m to $25m

×

AFT updates operating profit guidance to $23m to $25m

06 February 24

Maxigesic IV launched in the United States

×

Maxigesic IV launched in the United States

19 January 24

AFT further broadens R&D pipeline with new product candidate

×

AFT further broadens R&D pipeline with new product candidate

09 January 24

NEW YEAR LETTER TO INVESTORS

×

NEW YEAR LETTER TO INVESTORS

22 December 23

AFT broadens R&D pipeline with new product candidate

×

AFT broadens R&D pipeline with new product candidate

23 November 23

FY2024 Interim

×

FY2024 Interim

23 November 23

FY2024 Interim

×

FY2024 Interim

23 November 23

FY2024 Interim

×

FY2024 Interim

21 November 23

AFT Crystaderm antiseptic approved for sale in China

×

AFT Crystaderm antiseptic approved for sale in China

AFP Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock 0.18 N/A 0.14 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock 0.18 N/A N/A Lock Lock Lock
     Growth % Lock Lock Lock Lock 160.1 N/A N/A Lock Lock Lock
     PE X Lock Lock Lock Lock 24.7 26.1 18.2 Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock 0.0 18.4 12.6 Lock Lock Lock
CFPS $ Lock Lock Lock Lock 0.18 N/A N/A Lock Lock Lock
FCFPS $ Lock Lock Lock Lock 0.11 N/A 0.09 Lock Lock Lock
     Growth % Lock Lock Lock Lock 115.6 N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock 3.2 N/A N/A Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 N/A 0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock 0.0 0.8 0.6 Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 N/A 10 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.50 N/A 0.28 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.17 N/A 0.28 Lock Lock Lock
     Growth % Lock Lock Lock Lock 385.2 N/A N/A Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 105 N/A N/A Lock Lock Lock
Basic m Lock Lock Lock Lock 105 N/A N/A Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Income Statement
Sales $m Lock Lock Lock Lock 123 N/A 180 Lock Lock Lock
     Growth % Lock Lock Lock Lock 16.3 N/A N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 39 N/A 60 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 58 N/A N/A Lock Lock Lock
     Growth % Lock Lock Lock Lock 27.9 N/A N/A Lock Lock Lock
     Margin % Lock Lock Lock Lock 47.4 N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 53 N/A N/A Lock Lock Lock
EBITDA $m Lock Lock Lock Lock 20 N/A 24 Lock Lock Lock
     Growth % Lock Lock Lock Lock 91.4 N/A N/A Lock Lock Lock
     Margin % Lock Lock Lock Lock 16.3 N/A 13.4 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 1 N/A 1 Lock Lock Lock
EBIT $m Lock Lock Lock Lock 19 N/A 23 Lock Lock Lock
     Growth % Lock Lock Lock Lock 101.9 N/A N/A Lock Lock Lock
     Margin % Lock Lock Lock Lock 15.5 N/A 12.6 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock 18 N/A N/A Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -1 N/A N/A Lock Lock Lock
Net Income $m Lock Lock Lock Lock 19 N/A 14 Lock Lock Lock
     Growth % Lock Lock Lock Lock 157.5 N/A N/A Lock Lock Lock
     Margin % Lock Lock Lock Lock 15.2 N/A 8.0 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock 12 N/A 26 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 5 N/A 6 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock -5 N/A -9 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock -2 N/A -10 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock 11 N/A 4 Lock Lock Lock
     Growth % Lock Lock Lock Lock 576.6 N/A N/A Lock Lock Lock
     Margin % Lock Lock Lock Lock 0.1 N/A 0.0 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 7 N/A N/A Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 113 N/A 153 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 33 N/A N/A Lock Lock Lock
Net Debt $m Lock Lock Lock Lock 30 N/A 15 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 60 N/A N/A Lock Lock Lock
Equity $m Lock Lock Lock Lock 53 N/A 81 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 86 N/A N/A Lock Lock Lock
     Growth % Lock Lock Lock Lock 27.9 N/A N/A Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock 16.6 N/A 9.4 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock 35.6 N/A 17.8 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock 23.4 N/A N/A Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock 24.5 N/A N/A Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock 15.1 N/A N/A Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Leverage
Interest Cover X Lock Lock Lock Lock 8.1 N/A 9.1 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 1.5 N/A 0.6 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock 57.2 N/A 18.4 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 2.7 N/A N/A Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 1.5 N/A N/A Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 10.4 N/A N/A Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock 42.8 N/A 60.0 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 4.5 N/A N/A Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 2.1 N/A N/A Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 2.7 N/A N/A Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 9.1 N/A N/A Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 1.1 N/A 1.2 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 1.1 N/A 1.2 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock 14.3 N/A N/A Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock 15.6 N/A N/A Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock -6.2 N/A N/A Lock Lock Lock
Return on Assets % Lock Lock Lock Lock 16.6 N/A 9.4 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 2.1 N/A 1.9 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock 35.6 N/A 17.8 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 N/A 89.6 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock 35.6 N/A 15.9 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 175.1 N/A N/A Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 81.0 N/A N/A Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 256.1 N/A N/A Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 69.7 N/A N/A Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 186.4 N/A N/A Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

.6%

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Expected Dividend Cashflow

Dividend Clarity,
Enhanced
Strategy

Upload your portfolio and gain access to 3-year dividend forecasts for each holding with HALO Global. Empower your decision-making and maximize returns with our advanced analytical tool. Try it today.

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

AFP Shortsell

Frequently Asked Questions

The current share price of AFT Pharmaceuticals Ltd. (AFP:ASX) is AU$2.85.
The 52-week high share price for AFT Pharmaceuticals Ltd. (AFP:ASX) is AU$3.53.
The 52-week low share price for AFT Pharmaceuticals Ltd. (AFP:ASX)? is AU$2.43.
The current TTM dividend payout for AFT Pharmaceuticals Ltd. (AFP:ASX) is 0.60.
The last dividend payment of AFT Pharmaceuticals Ltd. (AFP:ASX) is AU$0.01.
AFT Pharmaceuticals Ltd. (AFP:ASX) has a franking level of 0.0%.
AFT Pharmaceuticals Ltd. (AFP:ASX) is classified in the Healthcare.
The current P/E ratio for AFT Pharmaceuticals Ltd. (AFP:ASX) is 18.20.
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.